These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27697997)

  • 1. Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy.
    Chaudary N; Pintilie M; Jelveh S; Lindsay P; Hill RP; Milosevic M
    Clin Cancer Res; 2017 Mar; 23(5):1242-1249. PubMed ID: 27697997
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
    Lecavalier-Barsoum M; Chaudary N; Han K; Pintilie M; Hill RP; Milosevic M
    Br J Cancer; 2019 Jul; 121(3):249-256. PubMed ID: 31239542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Oral CXCR4 Inhibitor X4-136 Improves Tumor Control and Reduces Toxicity in Cervical Cancer Treated With Radiation Therapy and Concurrent Chemotherapy.
    Chaudary N; Hill RP; Stulik L; Milosevic M
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1317-1324. PubMed ID: 33771702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the CXCL12/CXCR4 pathway and myeloid cells to improve radiation treatment of locally advanced cervical cancer.
    Lecavalier-Barsoum M; Chaudary N; Han K; Koritzinsky M; Hill R; Milosevic M
    Int J Cancer; 2018 Sep; 143(5):1017-1028. PubMed ID: 29417588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts.
    Chaudary N; Pintilie M; Hedley D; Hill RP; Milosevic M; Mackay H
    Br J Cancer; 2017 Jan; 116(1):50-57. PubMed ID: 27875522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
    Benedicto A; Romayor I; Arteta B
    Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
    Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
    Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
    Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
    J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway.
    Beider K; Rosenberg E; Bitner H; Shimoni A; Leiba M; Koren-Michowitz M; Ribakovsky E; Klein S; Olam D; Weiss L; Wald H; Abraham M; Galun E; Peled A; Nagler A
    Clin Cancer Res; 2017 Apr; 23(7):1733-1747. PubMed ID: 27697999
    [No Abstract]   [Full Text] [Related]  

  • 10. Combretastatin A4 nanodrug combined plerixafor for inhibiting tumor growth and metastasis simultaneously.
    Jiang J; Shen N; Song W; Yu H; Sakurai K; Tang Z; Li G
    Biomater Sci; 2019 Dec; 7(12):5283-5291. PubMed ID: 31603448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
    Han AR; Lee JY; Kim HJ; Min WS; Park G; Kim SH
    Oncol Rep; 2015 Dec; 34(6):2880-8. PubMed ID: 26398122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
    Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
    Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
    Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
    PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
    Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
    Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma.
    Lee EQ; Duda DG; Muzikansky A; Gerstner ER; Kuhn JG; Reardon DA; Nayak L; Norden AD; Doherty L; LaFrankie D; Stefanik J; Vardam T; Smith KH; McCluskey C; Gaffey S; Batchelor TT; Jain RK; Wen PY
    Clin Cancer Res; 2018 Oct; 24(19):4643-4649. PubMed ID: 29941486
    [No Abstract]   [Full Text] [Related]  

  • 16. [Correlation of CXCR4/CXCL12 overexpression to lymph node metastasis and chronic inflammation in cervical adenocarcinoma].
    Wei M; Liang LZ; Zhang CQ; Xiong Y; Zhang Y; Shen Y; Li JQ
    Ai Zheng; 2007 Mar; 26(3):298-302. PubMed ID: 17355795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
    Qiao N; Wang L; Wang T; Li H
    Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.
    Gravina GL; Mancini A; Colapietro A; Vitale F; Vetuschi A; Pompili S; Rossi G; Marampon F; Richardson PJ; Patient L; Patient L; Burbidge S; Festuccia C
    Tumour Biol; 2017 Jun; 39(6):1010428317695528. PubMed ID: 28639900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AGTR1 promotes lymph node metastasis in breast cancer by upregulating CXCR4/SDF-1α and inducing cell migration and invasion.
    Ma Y; Xia Z; Ye C; Lu C; Zhou S; Pan J; Liu C; Zhang J; Liu T; Hu T; Xie L; Wu G; Zhao Y
    Aging (Albany NY); 2019 Jun; 11(12):3969-3992. PubMed ID: 31219799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR4 antagonists suppress small cell lung cancer progression.
    Taromi S; Kayser G; Catusse J; von Elverfeldt D; Reichardt W; Braun F; Weber WA; Zeiser R; Burger M
    Oncotarget; 2016 Dec; 7(51):85185-85195. PubMed ID: 27835905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.